ARCHIVES

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

This article is from The Cancer Letter archive.

Vol. 25 No. 1 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

January 31, 2003

HHS News: Shalala Appoints Group On Genetic Testing

June 25, 1999

Also in this 8-page issue: David Hohn elected board chairman of the National Comprehensive Cancer Network.

March 26, 2004

UNC Lineberger Appoints Two, Zaret Wins Chair At Fox Chase.

February 25, 2000

TA To Release Report On Burton Therapy Requested By Congress

February 9, 1990

ACS Medals Of Honor To Bonadonna, Hsu, Louis Sullivan

December 13, 1991